Alpha-synuclein dimerization in erythrocytes of patients with genetic and non-genetic forms of Parkinson's Disease

Neurosci Lett. 2018 Apr 13:672:145-149. doi: 10.1016/j.neulet.2017.11.012. Epub 2017 Nov 10.

Abstract

Background: Variations of α-synuclein levels or species have been reported in Parkinson's Disease (PD). There has been little systematic examination of erythrocytes, a rich source of α-synuclein.

Methods: Erythrocyte membranes were obtained from PD patients (mutation carriers in the α-synuclein gene (A53T-PD) and glucocerebrosidase gene (GBA-PD) (n=18 each), and patients without known mutations (GU-PD, n=56)), and age-/sex-matched controls (n=56). Levels of monomeric and dimeric α-synuclein were assessed using Western immunoblotting.

Results: A statistically significant increase of α-synuclein dimer and dimer to monomer ratio was found in GBA-PD and GU-PD. In contrast, dimer levels of A53T-PD were not different from controls. No difference was found in α-synuclein monomer levels.

Conclusions: The increased α-synuclein dimer in GBA-PD and GU-PD is suggestive of an apparent systemic dysfunction causing the dimerization, and potentially oligomerization, of α-synuclein. These results may have implications for PD pathogenesis and biomarker development.

Keywords: Alpha-synuclein; Alpha-synuclein dimers; Alpha-synuclein oligomers; Erythrocytes; Glucocerebrosidase; Red blood cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Dimerization
  • Erythrocytes / metabolism*
  • Female
  • Glucosylceramidase / genetics
  • Glucosylceramidase / metabolism
  • Humans
  • Male
  • Middle Aged
  • Mutation
  • Parkinson Disease / genetics
  • Parkinson Disease / metabolism*
  • alpha-Synuclein / genetics
  • alpha-Synuclein / metabolism*

Substances

  • alpha-Synuclein
  • Glucosylceramidase